A new class
of drugs to treat
solid tumors
Aummune is a clinical stage company developing a first-of-its-kind approach for individualized treatment of solid tumors. Our proprietary platform utilizes a unique efficacy-driven selection process to match and produce a patient-specific tri-functional oligonucleotide drug that safely and synergistically induces cancer cell death and activates both innate and adaptive immune responses
Next-generation
individualized immunotherapy
Variable Strand
A tumor-targeting arm, selected for its
ability to bind the patient’s cancer cells
and induce cancer cell death while
avoiding effects on healthy tissue
ability to bind the patient’s cancer cells
and induce cancer cell death while
avoiding effects on healthy tissue
Bridge
A CpG-rich domain that fuses
the two strands and induces
Antigen Presenting Cells
stimulation through TLR9
the two strands and induces
Antigen Presenting Cells
stimulation through TLR9
Constant Strand
Engages immune effector
T cells, leading to
tumor cell lysis
T cells, leading to
tumor cell lysis
Tailoring the variable strand
to every patient
Sample processing
Propagating tumor cell samples
to generate 3D organoids
to generate 3D organoids
Efficacy-driven selection
Aummune’s platform screens the aptamer pool, selecting for a desired biological effect
Administration
The individually tailored therapy is administered to the patient
Personal drug assembly
Selected aptamer is manufactured and the individual therapeutic batch is assembled
Aummune’s benefits
New class of
therapy for
solid tumors
Pre-treatment
validated efficacy
Broad spectrum
of cancer
indications
Encouraging
preliminary
clinical data
AM003 – New class of individualized immunotherapy
AM003 is a unique, individualized therapy that has been designed to directly induce tumor cell death as well as to stimulate an anti-tumor immune response. The first-in-human Phase 1 is evaluating the safety and tolerability of AM003 in an open-label, multicenter, dose-escalation study of patients with locally advanced/metastatic solid tumors.
Leadership team
Let's Connect
Tel Aviv Medical Center (TAMC),
Sammy Ofer Building, Floor 10
Weizmann St 6, Tel Aviv-Yafo, ISRAEL
info@aummune.tech